Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Impaired uptake of glucose by skeletal muscle is a key feature of type 2 diabetes mellitus. It is unclear to what extent impaired insulin uptake from capillaries into skeletal muscle interstitium plays a role in this process.

We hypothesize that impaired uptake of insulin from capillaries into skeletal muscle interstitium is involved in impaired glucose uptake by skeletal muscle in type 2 diabetes mellitus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with type 2 diabetes mellitus

No interventions assigned to this group

Normoglycemic individuals

Control group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* written informed consent
* hemodynamically stable with a systolic blood pressure \> 100 mmHg
* medical need to undergo a CAG procedure as determined by cardiologist

* 30 years ≤ age ≤ 80 years (extremes included)
* fasting glucose level of \< 7.0 mmol/L and HbA1C \< 6.5% (= \< 48 mmol/mol)

* 30 years ≤ age ≤ 80 years (extremes included)
* fasting glucose level of \> 7.0 mmol/L, or HbA1C \> 6.5 (= \> 48 mmol/mol) or known T2DM

Exclusion Criteria

* ongoing myocardial infarction as determined from elevated cardiac markers
* participation in an investigational trial within 90 days prior to present study
* donation of blood (\> 100 mL) within 90 days prior to present study
* serious mental impairment or language problems i.e. preventing to understand the study protocol/aim
* Use or recent use (within 3 months of study participation) of oral glucocorticoids

\- known T2DM/use of glucose-lowering medication

\- treatment with insulin preparations

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

D van Raalte

MD PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kennemer Gasthuis

Haarlem, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KGINTDVR001

Identifier Type: -

Identifier Source: org_study_id